{"id":"rasi-plus-carvedilol","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Cough (RASi-related)"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL1201167","moleculeType":"Small molecule","molecularWeight":"504.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RASi (renin-angiotensin system inhibitor) blocks the formation or action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure and reducing cardiac workload. Carvedilol is a non-selective beta-blocker with alpha-blocking properties that decreases heart rate, contractility, and peripheral vascular resistance. Together, these agents provide complementary hemodynamic benefits for heart failure and hypertension management.","oneSentence":"This combination reduces blood pressure and improves heart function by blocking angiotensin II signaling (RASi) while simultaneously reducing heart rate and contractility through beta-blockade (carvedilol).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:54.263Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Hypertension"},{"name":"Post-myocardial infarction"}]},"trialDetails":[{"nctId":"NCT01557140","phase":"PHASE4","title":"A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2003-05","conditions":"Chagas Cardiomyopathy, Heart Failure, Dilated Cardiomyopathy","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Randomized","Double blind","Controlled","Trial"],"phase":"marketed","status":"active","brandName":"RASi plus carvedilol","genericName":"RASi plus carvedilol","companyName":"Federal University of Minas Gerais","companyId":"federal-university-of-minas-gerais","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood pressure and improves heart function by blocking angiotensin II signaling (RASi) while simultaneously reducing heart rate and contractility through beta-blockade (carvedilol). Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}